English हिंदी BRIC
  • ट्रांसलेशनल हेल्थ साइंस एंड टेक्नोलॉजी इंस्टीट्यूट
  • TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE
    AN INSTITUTE OF BIOTECHNOLOGY RESEARCH AND INNOVATION COUNCIL
    DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY
    GOVT OF INDIA
  • होम
  • संकाय प्रोफ़ाइल

DR.RUCHI TANDON

Ph.D.

SENIOR RESEARCH SCIENTIST

  • Ph.D.
  • PhD, CSIR-Central Drug Research Institute, Lucknow (Immunomodulators)
  • Postdoctoral Research Associate, National Institute of Immunology, New Delhi
  • Postdoctoral Research Associate, Wayne State University, MI, USA (Metabolic Disorders and Oncology)
  • Drug Discovery Research: Led and managed the discovery portfolio of early discovery programs on complex human diseases such as metabolic and inflammatory disorders as well as oncology utilizing the small molecule and natural products formulations for their pre-clinical development while working with inter-disciplinary institutional and global teams in leading pharmaceutical companies during 2002-2017.

 

Current Interests: Metabolic-associated Fatty Liver Disease

NAFLD is a slow-progressing disease with aberrant lipid metabolism, inflammation, oxidative stress, and fibrosis which has nearly 30 % global prevalence with no treatment options available to date. Current focus of my lab is to understand the pathophysiology and identify potential therapeutic options for the management of Metabolic-associated Fatty Liver Disease (MAFLD) and associated comorbidities.

My lab has established in vitro and in vivo models to perform pre-clinical assesment of small chemical entities as well as natural product formulations to identify potential therapeutic options for the management of NAFLD. 

Apart from conventional 2D models my lab has established multilineage 3D spheroid models mimicking the liver heterogeneity to test the anti-steatotic, anti-inflammatory and anti-fibrotic properties of test compounds.

Short-listed molecules as a result of this exercise are further evaluated for their pharmaco-kinetic analysis followed by screening in the in vivo models of NAFLD using mice fed with different types of carbohydrate and fat rich diets.  

My lab also has a keen interest in understanding the role of different members of inflammasome family in progression of NAFLD and their correlation with different diets in animals and patients using metabolites and gene expression studies in different metabolic tissues.   

/var/folders/d3/_xrxflp51r99k2z8zcf7n4340000gn/T/com.microsoft.Word/Content.MSO/E01F0D47.tmp                                                                                               

Establishment of Liver Organoid Platform

To overcome the issues related to the translation of the in vitro findings into the in vivo set ups and later at the clinical stage, we need more realistic screening models. My lab has therefore established human liver organoids using healthy humans and NAFLD patients derived liver tissues as a platform to conduct drug discovery research and to understand the pathophysiology of NAFLD. (J Clin Exp Hepatol, 2024 https://doi.org/10.1016/j.jceh.2024.102463)

/var/folders/d3/_xrxflp51r99k2z8zcf7n4340000gn/T/com.microsoft.Word/Content.MSO/65E6ADED.tmp

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publication

Recent Publications

§ Kamala MRP, Reddy PN1, GoswamiY, DwivediW, PujaniM, DikshitM, Tandon R.* AYUSH-64 Modulates Th17/Treg Balance to Attenuate LPS-Induced Inflammation in Cell-   Based Assays and BALB/c Mice Model. Pharmacological Research-Natural Products, Accepted Jan 2025 (Article in Press)(*Corresponding Author)

§ Goswami Y, Baghel A, Sharma G, Sharma PK, Biswas S, Yadav R, Garg PK, Shalimar, Tandon R*. Liver organoids from hepatocytes of healthy humans and non-alcoholic fatty liver disease (NAFLD) patients display multi-lineage architecture and can be used to develop an in vitro model of steatohepatitis Journal of Clinical and Experimental Hepatology, Articles in Press102463December 03, 10.1016/j.jceh.2024.102463 (*Corresponding Author)

 

§ Kumari D, Gautam J, Sharma V, Gupta S, Sarkar S, Jana P, Singhal V, Babele P, Kamboj P,  Bajpai S, Tandon R, Kumar Y, Dikshit M. Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice, HELIYON (2023), doi:       https:// doi.org/10.1016/j.heliyon.2023.e22051.

 

§ Sharma PK, Verma L, Goswami Y, Pujani M, Dikshit M*, Tandon R* The aqueous root extract of Withania somnifera ameliorates LPS-induced inflammatory changes in the in vitro cell-based and mice models of inflammation Front. Pharmacol., (2023)14:1139654. doi: 10.3389/fphar.2023.1139654 (*Corresponding Author)

 

§ Sharma P, Nandave M, Nandave D, Yadav S, De-Le_Cruz CV, Singh S, Tandon R, Ramniwas S, Behl T. Reactive oxygen species(ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants. Am J Trans Research. 2023, 15(10)

 

§ Goyal C, Tandon R*.USP30 Inhibitors and Mitophagy, a Cellular Power Couple against Metabolic-Associated Fatty Liver Disease, Advances in Pharmacology & Clinical Trials, (2024) 9(3) ISSN:2474-9214. DOI: 10.23880/apct-16000248(*Corresponding author)

 

§Tandon, R*., Kumar, P. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells. In: Nandave, M., Jain, P. (eds) PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics. Springer,  Singapore (2024). https://link.springer.com/chapter/10.1007/978-981-97-5077-1_14  (*Corresponding author)

 

§ Soni A, Saha S, Agarwal A, Rauf ARA, Singh RK, Seth M,   Singh SK, Sinha S, Shirumalla RK, Marumoto S, Tandon R* 2-{N-[(2,4,5-trichlorophenoxy) acetyl]-N-methylamino}-3-pyrrolidinepropanamides analogs as potential antagonists of Urotensin-II receptor,  J Recep Sig Trans, 2022, 2023 Feb;43(1):1-8. doi: 10.1080/10799893.2022.2164306. Epub 2023 Jan 18. (*Corresponding author).

 

§  Visaga SA,  Kalonia H,  Verma V,  Sinha S,  Singh SK,  Upadhyay S, Sahdev S,  Pansari P,  Kumar R,  Bandgar M, Karanjule N, Shirumalla RK,  Morishita K, Tandon   R* Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma(2022) J Clin Toxicol, Vol.12 (3)1000510 (*Corresponding author)

 

§  Singh RK, Sodhi R, Sharma S, Dastidar SG, Tandon R*. Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitors. BioRxiv doi:https://doi.org/10.1101/2022.07.17.500377 2022 (*Corresponding author)

 

 

2020 and earlier

§  Tandon R*, Soni A., Singh R.K., Sodhi R., Seth MK.,  Sinha S., Dhage G., Das B., Dastidar SG, Shriumalla RK. Marumoto S, Nagayama T. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice (2020) Euro J Pharmacol  886:173391.DOI: 10.1016/j.ejphar.2020.173391, PMID: 32745605 (*Corresponding author)

 

§  Soni A, Agarwal A, Saha S, Shripati KR, Das M, Das B, Cliffe I, Tandon R, Singh RK, Dastidar S, Singh SK, Sinha S, Shriumalla RK, Semwal VP, Marumoto S, Nagayama T. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as Urotensin-II receptor antagonists, 250th American Chem Soc.  National Meetings and Expositions, Boston, MA, USA, 2015

 

§  Tandon R*, Senthil V., Nithya D., Venkataramanan R.,  Pamidiboina V., Kumar A, Malik S, Chaira T, Diwan M, Gupta P, Venkataramanan R, Malik R, Das B, Dastidar SG, Cliffe IA; Ray A; Bhatnagar PK. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy (2013) Euro J Pharmacol 711(1-3):19-26. DOI: 10.1016/j.ejphar.2013.04.016PMID: 23639757(*Corresponding author)

 

§  Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthma (2013) J Asthma 50(9):922-931.    DOI: 10.3109/02770903.2013.823447PMID: 23859232 

 

§  Tandon R*, Kapoor S, Vali S, Senthil V., Nithya D., Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK and Dastidar SG. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment (2011) Euro  J Pharmacol 667(1-3):5665. DOI: 10.1016/j.ejphar.2011.04.066  PMID: 21640718  (Corresponding author)

 

§ Tiwari P, Saini S,  Upmanyu S, Benjamin B,  Tandon R, Saini KS and Sahdev S. Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector.(2010) Mol  Biotechnology 46(1):80-9.  DOI: 10.1007/s12033-010-9284-3 PMID: 20424933

 

§  Tandon R, Singh MP, Haq W, Dixit M, Patnaik GK and Dhar MM (2010) Design and synthesis of novel tetrapeptides as potential ACE inhibitors.Cheminformatics 28, 40.

 

§  Subhadra LB,  Sundaresan S,  Singaravelu A,  Kadapakkam SN,  Badri NR, Katiyar C,  Kanaujia  A, Duggar R, Singh Y,  Konasubrahmanya S,  Bansal V, Sarin S,  Tandon   R,  Sharma S and Singh S. (2009) Cinnamic acid isolated from the bark of Cinnamomum cassia regulates glucose transport through activation of glucose transporter 4 on L6 myotubes in a PI3 Kinase independent fashion. J Diabetes 1, 99-106. DOI: 10.1111/j.1753-0407.2009.00022.xPMID: 20929506

 

§  Soni A, Agarwal A, Saha S, Das M, Shripati K, Aeron S, Das B, Cliffe I, Tandon R, Singh R, Sodhi R. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as urotensin-II receptor antagonists. Abstracts of the papers of the American Chemical Society 2015 Aug 16 (Vol. 250). 1155 16TH ST, NW, Washington, DC 20036 USA: AMER CHEMICAL SOC.

 

§ Tandon R*, Gupta A, Ray A (2013)  Mechanism of action of antidiabetic property of cinnamic acid, a principal active ingredient from the bark of Cinnamomum cassia. Int J Therap Appls, 9, 2013, 39-45.  (*Corresponding author)

 

§  Zhang M, Deng Y, Tandon R, Bai C, Riedel H. ( 2008) Essential role of PSM/SH2-B variants in insulin receptor catalytic activation and the resulting cellular responses J Cell Biochem, 1;103(1):162-81. DOI: 10.1002/jcb.21397PMID: 17615553

 

§  Sarma PK, Tandon R, Gupta P, Dastidar SG, Ray A, Das B, Cliffe IA(2007) Progress in the  development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase. Exp Opin Ther Pat 17(1) 25-35 (11) https://doi.org/10.1517/13543776.17.1.25

 

§ Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L,  Khattar SK, Bora RS, Saini KS, Bansal VS (2007) Increase in weight induced by muraglitazar, a dual PPAR alpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol, 150(4):480-7.  DOI: 10.1038/sj.bjp.0707000 PMID: 17211457

 

§  Deng Y, Bhattacharya S, Swamy OR, Tandon R, Wang Y, Janda R, Riedel H.(2003) Growth factor receptor binding protein 10 (Grb10) as a partner of PI 3kinase in metabolic insulin action. J Biol Chem; 278(41):39311-22.   DOI: 10.1074/jbc.M304599200PMID: 12783867 

 

§  Singh SB*, Tandon R*, Krishnamurthy G, Vikram R, Sharma N, Basu SK and Mukhopadhyay A (2003) Rab5-mediated   endosome-endosome fusion.  Regulates.  hemoglobin endocytosis in Leishmania donovani. EMBO J; 22(21):5712-22.   DOI: 10.1093/emboj/cdg557PMID: 14592970 (Co-first author*)

 

§  Narayan P, Pandey R, Yadav VS, Tandon R, Haq W, Dhar MM, Singh VK (2003). Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation.  by peptidomimetic opioid compound. Immunopharmacol Immmunotox;25(2):225-33. DOI: 10.1081/iph-120020472  PMID: 12784915

 

§ Narayan P, Tandon R, Haq W, Dhar and MM Singh VK (2002) Inhibition of antigen-specific lymphocyte proliferation and cytokine stimulation by peptidomimetic opioid compound. Int Immunopharmacol 2:751-757. DOI: 10.1016/s1567-5769(02)00011-5PMID: 12095165

 

§  Narayan P, Singh VK, Agarwal SS, Tandon R, Haq W, Raghubir R and Dhar MM (2001) Immunomodulation by Opioid Peptidomimetic   Compound. Neuroimmunomodulation 9:134-40.   doi: 10.1159/000049017. PMID: 11752886

 

§  Sengupta S, Tripathi J, Tandon R, Roy RP, Basu SK and Mukhopadhyay A (1999) Hemoglobin endocytosis in Leishmania is mediated through a 46 kD protein located in flagellar pocket. J Bio Chem  274(5), 2758-2765.  DOI: 10.1074/jbc.274.5.2758PMID: 9915807

 

§ Tandon R, Singh MP, Haq W, Dikshit' M, Patnaik  GK, Dhar MM (1997), Synthesis of novel tetrapeptides as potential ACE inhibitors. I J Chem, 36B.

 

§  Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H  (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator alpha mRNA, complete cds, alternatively spliced. NCBI GenBank; Accession number AF421138.

 

§  Yousaf  N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator gamma mRNA,   complete cds, alternatively spliced. NCBI GenBank Accession number AF421139.

 

§  Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001). Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank Accession   number AF380422.

·      Pallerla Naveen Reddy, Deependra Singh, Vivek Dave, and Ruchi Tandon.  Applications of Nanocomposites for 3d and 4d Printing of Nanomaterials in Biomedical Research. Apple Academic Press, Nanocomposites and Nanomaterials in Biomedical Applications, Edi: Vivek Dave, Deependra Singh, Pallerla Naveen Reddy.

·      Tandon, R*, Kumar, P. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells. In: Nandave, M., Jain, P. (eds) PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics. Springer Nature,  Singapore (2024). https://link.springer.com/chapter/10.1007/978-981-97-5077-1_14  (*Corresponding author).

 

1.     Liver Organoid model using healthy persons and NAFLD patient-derived hepatocytes to overcome the challenges of preclinical screening for steatohepatitis. Investigators:     Ruchi Tandon, Yamini Goswami, Akash Baghel. New provisional Patent Application (Application no. 202411081650). Issued by Indian Patent Office.

 

2.     Novel formulations containing gut microbiota derived metabolites of dietary Tryptophan for the management of Non-alcoholic Fatty Liver Disease. Investigators: Ruchi Tandon, Phulwanti Kumari Sharma, Yamini Goswami, Ruby Bansal. Patent Application (Application no. 202311016126).

 

3.     Filed a patent on Imidazopyridine class of compounds as kinase inhibitors (2009) Ranbaxy Res Labs.

 

4.     Heat shock protein inducers in myocardial and cerebral ischemia. (2004) Torrent Pharmaceuticals ltd. Gujarat, ndia, Pct File No. Pct/in05/00112, Indian Patent File No. 178/kol/2004.

 

5.     2-propene-1-ones as hsp 70 inducers, Torrent Pharmaceuticals Ltd. Gujarat, India, (International Patent Application number CA2562130C).

 

6.     An improved process for the preparation of polypeptide useful as a Gonadotropin-Releasing Hormone agonist having C-Terminal Proline ethyl amide". Central Drug Research Institute, Lucknow, India (Patent application No.3069/DEL/97).

 

 

  • Appointed as Finance Secretary (Treasurer) International Academy of Cardiovascular Sciences, 2025

  • Appointed as Member, Editorial Board: Molecular and Cellular Biochemistry, 2025

  • Appointed as Member, Editorial Board: Scripta Medica, 2025

  • Appointed as Review Editor on the Editorial Board of Frontiers Journals., 2022

  • Assistant Director and Group Head, Pharmacology, Daiichi Sankyo Pharma, 2014

  • Assistant Director, Daiichi Sankyo Pharma, 2010Group Head Pharmacology, 2012

  • Star Team award, Daiichi Sankyo, 2012

  • SMART Team award, Daiichi Sankyo, 2013

  • Reviewer international peer reviewed journals; PLOS One, Oncology Rev and Frontiers in Pharmacology, Biomedicine and Pharmacotherapy, Molecular and Cellular Biochemistry, Life Sciences, European J Pharmacology

  • Individual Excellence Award, Ranbaxy Research Labs, 2006

  • Postdoctoral Research Associate, Wayne State University, MI, USA (National Institute of Health, Bethesda, USA Fellowship) 2000

  • International Travel Award: Research Centre for Biotechnology, Braunschweig, Germany, 1999

  • CSIR Fellowship 1997  

NCBI Nucleotide Accessions 

1- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator alpha mRNA, complete     cds, alternatively spliced. NCBI GenBank accession number AF421138, GI: 16226080 

2- Yousaf N, DengY, Tandon R, Cheng DW, KangY and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator gamma mRNA, complete       cds, alternatively spliced. NCBI GenBank accession number AF421139, GI 16226077

3- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001) Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank accession   number  AF380422, GI: 15787982

  • 01292876487
  • RUCHI[DOT]TANDON[AT]THSTI[DOT]RES[DOT]IN